公开(公告)号：US07754712B2

公开(公告)日：2010-07-13

申请号：US11951097

申请日：2007-12-05

Applicant: Simeon Bowers ,  Albert W. Garofalo ,  Roy K. Hom ,  Andrei W. Konradi ,  Matthew N. Mattson ,  Martin L. Neitzel ,  Christopher M. Semko ,  Anh P. Truong ,  Jing Wu ,  Ying-zi Xu

Inventor： Simeon Bowers ,  Albert W. Garofalo ,  Roy K. Hom ,  Andrei W. Konradi ,  Matthew N. Mattson ,  Martin L. Neitzel ,  Christopher M. Semko ,  Anh P. Truong ,  Jing Wu ,  Ying-zi Xu

IPC: A61K31/5365 ,  A61K31/437 ,  A61K31/4985 ,  A61P25/28 ,  C07D497/04 ,  C07D497/14 ,  C07D471/14

CPC classification number: C07D451/14 ,  C07D471/08 ,  C07D471/18 ,  C07D471/22 ,  C07D498/08

Abstract: The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.

Abstract translation: 本发明提供了N-环磺酰氨基化合物和式I的盐：其中A如说明书中所述，并且R 1和R 2结合形成[3.3.1]或[3.2.1]环体系，其中氮被连接 并且[3.3.1]或[3.2.1]环体系任选地与杂芳基或杂环烷基环稠合。 式I的化合物可用于治疗或预防认知障碍，例如阿尔茨海默病。 本发明还包括含有式I化合物的药物组合物，治疗认知障碍的方法，例如阿尔茨海默氏病，以及可用于制备式I化合物的中间体。

公开(公告)号：US07432379B2

公开(公告)日：2008-10-07

申请号：US10837231

申请日：2004-04-30

Applicant: Jay S. Tung ,  Albert W. Garofalo ,  Michael A. Pleiss ,  Jing Wu ,  David W. G. Wone ,  Ashley C. Guinn ,  Darren B. Dressen ,  R. Jeffrey Neitz ,  Jennifer Marugg ,  Martin Neitzel

Inventor： Jay S. Tung ,  Albert W. Garofalo ,  Michael A. Pleiss ,  Jing Wu ,  David W. G. Wone ,  Ashley C. Guinn ,  Darren B. Dressen ,  R. Jeffrey Neitz ,  Jennifer Marugg ,  Martin Neitzel

IPC: C07D401/12

CPC classification number: C07D401/14 ,  C07D231/16 ,  C07D231/40 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/08 ,  C07D487/08

Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

Abstract translation: 公开了缓激肽B 1受体拮抗剂的化合物，并且可用于治疗由缓激肽B 1受体介导的哺乳动物中疾病或与疾病状况相关的不良症状。 某些化合物表现出增加的效力，并且还预期表现出增加的作用持续时间。

公开(公告)号：US07257603B2

公开(公告)日：2007-08-14

申请号：US10435712

申请日：2003-05-08

Applicant: Derek Murman ,  Edward H. Wayt ,  Jeffrey Bisset ,  Jing Wu ,  Kim Cameron ,  Max L. Benson ,  Jie Liu

Inventor： Derek Murman ,  Edward H. Wayt ,  Jeffrey Bisset ,  Jing Wu ,  Kim Cameron ,  Max L. Benson ,  Jie Liu

IPC: G06F17/30

CPC classification number: G06Q10/06 ,  Y10S707/99942 ,  Y10S707/99943 ,  Y10S707/99945 ,  Y10S707/99948 ,  Y10S707/99952

Abstract: Various exemplary metadirectories, systems and/or methods include or allow for executing a software module on an execution engine, emitting semantic information based on the executing, and analyzing the executing using the semantic information. An exemplary execution engine includes an input for receiving software modules, an output for emitting semantic information, and an output for outputting generated output information. Upon execution, an exemplary software module may cause processing of information in a metadirectory and emitting of semantic information pertaining to the processing. Various exemplary metadirectories, systems and/or methods emit and/or store semantic information in a self-defining language, an extensible language, and/or a markup language. Other exemplary metadirectories, systems, and/or methods are also disclosed.

Abstract translation: 各种示例性的元数据，系统和/或方法包括或允许在执行引擎上执行软件模块，基于执行发送语义信息，并且使用语义信息来分析执行。 示例性执行引擎包括用于接收软件模块的输入，用于发出语义信息的输出，以及用于输出生成的输出信息的输出。 在执行时，示例性软件模块可以引起对元目录中的信息的处理并发出与该处理有关的语义信息。 各种示例性的元目录，系统和/或方法以自定义语言，可扩展语言和/或标记语言发出和/或存储语义信息。 还公开了其它示例性的元目录，系统和/或方法。

公开(公告)号：US20070161633A1

公开(公告)日：2007-07-12

申请号：US10555515

申请日：2004-04-30

Applicant: Jay Tung ,  Albert Garofalo ,  Michael Pleiss ,  Jing Wu ,  David Wone ,  Ashley Guinn ,  Darren Dressen ,  Jennifer Marugg ,  Martin Neitzel

Inventor： Jay Tung ,  Albert Garofalo ,  Michael Pleiss ,  Jing Wu ,  David Wone ,  Ashley Guinn ,  Darren Dressen ,  Jennifer Marugg ,  Martin Neitzel

IPC: A61K31/5377 ,  A61K31/496 ,  A61K31/454 ,  A61K31/4152 ,  C07D413/02 ,  C07D403/02

CPC classification number: C07D401/14 ,  C07D231/16 ,  C07D231/40 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/08 ,  C07D487/08

Abstract: Disclosed are compounds of formulae (I) and (II) that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action. Wherein Z is selected from O, S and NH; Q of formula (III) and the other substituents are as defined in claim 1.

Abstract translation: 公开了缓激肽B 1受体拮抗剂的式（I）和（II）化合物，并且可用于治疗由缓激肽B介导的哺乳动物中的疾病或减轻与疾病相关的不良症状B _{1 受体。 某些化合物表现出增加的效力，并且还预期表现出增加的作用持续时间。 其中Z选自O，S和NH; 式（III）的Q和其它取代基如权利要求1中所定义。}

公开(公告)号：US20060193387A1

公开(公告)日：2006-08-31

申请号：US11339825

申请日：2006-01-26

Applicant: Jing Wu ,  Alison Lennon

Inventor： Jing Wu ,  Alison Lennon

IPC: H04N11/02 ,  H04N9/64 ,  H04N7/12 ,  H04B1/66 ,  H04N11/04

CPC classification number: G06F17/30843 ,  G06F17/30811 ,  G06K9/00711 ,  G11B27/28 ,  H04N19/527 ,  H04N19/61

Abstract: A method of extracting key frames from a video sequence, which video sequence comprises MPEG compressed video data having block motion vectors. The method initially partially decompresses (202) the MPEG compressed video data to obtain block motion vectors and converts (204) the block motion vectors to forward block motion vectors. The method then generates (206) global motion signals and generates (306) dominant global direction clusters. The method then selects (402,404,406) potential key frames of the video sequence using the generated dominant global direction clusters. The method lastly decompresses (408) the selected key frames to obtain the extracted key frames.

Abstract translation: 一种从视频序列中提取关键帧的方法，该视频序列包括具有块运动矢量的MPEG压缩视频数据。 该方法最初部分地解压缩（202）MPEG压缩视频数据以获得块运动矢量，并将块运动矢量转换（204）以转发块运动矢量。 该方法然后产生（206）全局运动信号并产生（306）主要全局方向簇。 然后，该方法使用所产生的主导全局方向簇来选择视频序列的潜在关键帧（402,404,406）。 该方法最后解压缩（408）所选择的关键帧以获得提取的关键帧。

公开(公告)号：US20050038099A1

公开(公告)日：2005-02-17

申请号：US10836929

申请日：2004-04-30

Applicant: Jay Tung ,  Albert Garofalo ,  Michael Pleiss ,  Jing Wu ,  David Wone ,  Ashley Guinn ,  Darren Dressen ,  Jennifer Marugg ,  Martin Neitzel

Inventor： Jay Tung ,  Albert Garofalo ,  Michael Pleiss ,  Jing Wu ,  David Wone ,  Ashley Guinn ,  Darren Dressen ,  Jennifer Marugg ,  Martin Neitzel

IPC: A61P29/00 ,  C07D231/16 ,  C07D231/40 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/08 ,  C07D487/08 ,  A61K31/416 ,  A61K31/4152

CPC classification number: C07D401/14 ,  C07D231/16 ,  C07D231/40 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/08 ,  C07D487/08

Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

Abstract translation: 公开了缓激肽B1受体拮抗剂的化合物，可用于治疗由缓激肽B1受体介导的哺乳动物中疾病或与疾病状况相关的不良症状。 某些化合物表现出增加的效力，并且还预期表现出增加的作用持续时间。

公开(公告)号：US20050032868A1

公开(公告)日：2005-02-10

申请号：US10836903

申请日：2004-04-30

Applicant: Albert Garofalo ,  Jay Tung ,  Michael Pleiss ,  Jing Wu ,  David Wone ,  Ashley Guinn ,  Darren Dressen ,  Jennifer Marugg ,  Martin Neitzel

Inventor： Albert Garofalo ,  Jay Tung ,  Michael Pleiss ,  Jing Wu ,  David Wone ,  Ashley Guinn ,  Darren Dressen ,  Jennifer Marugg ,  Martin Neitzel

IPC: A61K31/4152 ,  A61K31/416 ,  C07D231/16 ,  C07D231/40 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D43/02

CPC classification number: C07D401/12 ,  C07D231/16 ,  C07D231/40 ,  C07D403/12 ,  C07D417/12

Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

Abstract translation: 公开了缓激肽B1受体拮抗剂的化合物，可用于治疗由缓激肽B1受体介导的哺乳动物中疾病或与疾病状况相关的不良症状。 某些化合物表现出增加的效力，并且还预期表现出增加的作用持续时间。

公开(公告)号：US06495693B2

公开(公告)日：2002-12-17

申请号：US09280966

申请日：1999-03-30

Applicant: James E. Audia ,  Beverly K. Folmer ,  Varghese John ,  Lee H. Latimer ,  Jeffrey S. Nissen ,  Warren J. Porter ,  Eugene D. Thorsett ,  Jing Wu

Inventor： James E. Audia ,  Beverly K. Folmer ,  Varghese John ,  Lee H. Latimer ,  Jeffrey S. Nissen ,  Warren J. Porter ,  Eugene D. Thorsett ,  Jing Wu

IPC: C07D27782

CPC classification number: C07D215/38 ,  A61K31/00 ,  A61K31/198 ,  A61K31/223 ,  C07C237/08 ,  C07C237/10 ,  C07C237/12 ,  C07C271/22 ,  C07D209/20 ,  C07D233/64 ,  C07D277/62 ,  C07D277/82

Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Abstract translation: 公开了抑制β-淀粉样蛋白肽释放和/或其合成的化合物，因此具有治疗阿尔茨海默病的效用。 还公开了包含抑制β-淀粉样蛋白肽释放和/或其合成的化合物的药物组合物以及用这种药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。

公开(公告)号：US06207710B1

公开(公告)日：2001-03-27

申请号：US09164385

申请日：1998-09-30

Applicant: James E. Audia ,  Thomas C. Britton ,  James J. Droste ,  Beverly K. Folmer ,  George W. Huffman ,  Varghese John ,  Lee H. Latimer ,  Thomas E. Mabry ,  Jeffrey S. Nissen ,  Warren J. Porter ,  Jon K. Reel ,  Eugene D. Thorsett ,  Jay S. Tung ,  Jing Wu

Inventor： James E. Audia ,  Thomas C. Britton ,  James J. Droste ,  Beverly K. Folmer ,  George W. Huffman ,  Varghese John ,  Lee H. Latimer ,  Thomas E. Mabry ,  Jeffrey S. Nissen ,  Warren J. Porter ,  Jon K. Reel ,  Eugene D. Thorsett ,  Jay S. Tung ,  Jing Wu

IPC: A01N3712

CPC classification number: A61K31/00 ,  A61K38/05 ,  A61K38/06 ,  C07K5/06078 ,  C07K5/06191

Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis.

Abstract translation: 公开了抑制β-淀粉样蛋白肽释放和/或其合成的化合物，因此具有治疗阿尔茨海默病的效用。 还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物。

公开(公告)号：US06191166B1

公开(公告)日：2001-02-20

申请号：US08976289

申请日：1997-11-21

Applicant: James E. Audia ,  Thomas C. Britton ,  James J. Droste ,  Beverly K. Folmer ,  George W. Huffman ,  John Varghese ,  Lee H. Latimer ,  Thomas E. Mabry ,  Jeffrey S. Nissen ,  Warren J. Porter ,  Jon K. Reel ,  Eugene D. Thorsett ,  Jay S. Tung ,  Jing Wu ,  Clark Norman Eid ,  William Leonard Scott

Inventor： James E. Audia ,  Thomas C. Britton ,  James J. Droste ,  Beverly K. Folmer ,  George W. Huffman ,  John Varghese ,  Lee H. Latimer ,  Thomas E. Mabry ,  Jeffrey S. Nissen ,  Warren J. Porter ,  Jon K. Reel ,  Eugene D. Thorsett ,  Jay S. Tung ,  Jing Wu ,  Clark Norman Eid ,  William Leonard Scott

IPC: A01N3712

CPC classification number: C07K5/06191 ,  A61K31/00 ,  A61K31/4015 ,  A61K31/405 ,  A61K31/445 ,  A61K31/47 ,  A61K38/05 ,  A61K38/06 ,  C07K5/06078

Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Abstract translation: 公开了抑制β-淀粉样蛋白肽释放和/或其合成的化合物，因此具有治疗阿尔茨海默病的效用。 还公开了包含抑制β-淀粉样蛋白肽释放和/或其合成的化合物的药物组合物以及用这种药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。